Do personalised cancer vaccines change prevention after 40?

Text written with the help of AI.

A personalised cancer vaccine sounds like something you might eventually add to a prevention plan. The latest melanoma findings concern a different situation: people whose cancer has already been surgically removed. For adults over 40 following longevity research, the useful question is whether better protection against recurrence changes what you should do before cancer develops.

The vaccine starts with a tumour that already exists

Intismeran autogene, previously called V940 or mRNA-4157, is designed around mutations in an individual patient’s tumour. Researchers use those mutations to select targets called neoantigens, abnormal protein features that the immune system may recognise. The resulting mRNA treatment supplies instructions for producing those targets, with the aim of directing an immune response against cancer cells. This is the personalisation described by Merck and Moderna in their August 2026 trial announcement.

The starting material matters. This approach uses information from a diagnosed cancer. It does not demonstrate that a vaccine can anticipate whichever cancer a healthy person might develop.

The US National Cancer Institute distinguishes treatment vaccines from prevention vaccines on precisely this basis: treatment vaccines target cancer cells in people who have cancer. “Vaccine” describes an immune-training approach; the word alone does not tell you whether its purpose is prevention or treatment. NCI, cancer treatment vaccines.

Established evidence: immunotherapy can reduce recurrence after surgery

The new vaccine is being tested alongside pembrolizumab, also known as Keytruda. This drug blocks PD-1, an immune checkpoint involved in restraining T-cell activity. Blocking that signal can allow immune cells to attack cancer. The vaccine is intended to help direct recognition towards selected tumour targets. NCI, 2022.

Pembrolizumab already has randomised evidence in this setting. In the European Organisation for Research and Treatment of Cancer’s KEYNOTE-054 trial, published in 2018, it improved recurrence-free survival compared with placebo after surgery for high-risk stage III melanoma. Eggermont and colleagues, *New England Journal of Medicine*, 2018.

That established evidence makes the new comparison useful. Investigators are asking whether adding a personalised vaccine improves outcomes beyond an active treatment. They are not comparing it with doing nothing.

Emerging evidence: what the Phase III result actually measures

INTerpath-001 enrolled 1,137 patients with completely removed, high-risk stage IIB to IV cutaneous melanoma. Participants were randomly assigned to intismeran plus pembrolizumab or placebo plus pembrolizumab in a double-blind trial. Merck and Moderna, August 2026.

The companies’ detailed release on 22 October reported a median follow-up of 24.6 months. Estimated recurrence-free survival at two years was 82.2% with the combination and 70.0% with pembrolizumab alone. The hazard ratio for recurrence or death was 0.58, with a 95% confidence interval of 0.45 to 0.75. These are sponsor-reported Phase III findings; the release stated that publication had been accepted by the New England Journal of Medicine. Merck and Moderna, October 2026.

Subtracting the two reported rates gives a 12.2 percentage-point difference at two years. That is the relevant absolute comparison. The headline “42% reduction” expresses a relative reduction in the hazard of recurrence or death over follow-up. It does not mean that 42 additional people out of every 100 avoided recurrence.

Recurrence-free survival is a clinical outcome, not merely a change in an immune marker. Nevertheless, it combines recurrence and death into one endpoint. An improvement cannot, by itself, establish how much longer patients live.

Longer follow-up strengthens the case, without answering every question

The earlier KEYNOTE-942 trial provides a different piece of evidence: more time, but fewer participants.

Its original peer-reviewed report included 157 patients. At the initial analysis, the confidence interval for the recurrence-or-death hazard ratio extended slightly above 1, the value indicating no difference. That uncertainty was one reason a larger trial mattered. Weber and colleagues, *The Lancet*, 2024.

The five-year update, published in 2026, continued to favour the combination for recurrence-free and distant metastasis-free survival. However, these later analyses were descriptive. Overall survival remained uncertain, with only seven deaths in each treatment group and unequal group sizes. Its confidence interval still included no difference. Khattak and colleagues, *Journal of Clinical Oncology*, 2026.

Together, the studies support a more credible treatment signal than either could provide alone. They should not be blended into a claim that the larger trial already has five years of follow-up.

The Phase III release also describes overall survival data as immature. For a longevity reader, that leaves a specific unanswered question: whether fewer recurrences will translate into longer survival, and by how much. Merck and Moderna, October 2026.

Personalisation does not remove treatment risks

In the Phase III disclosure, grade 3 to 5 treatment-related adverse events occurred in 14.2% of combination recipients and 13.4% of controls. Fever, injection-site pain and fatigue were common with the combination. Merck and Moderna, October 2026.

Similar rates between groups do not make either regimen harmless. Both groups received pembrolizumab. Checkpoint inhibitors can cause inflammation affecting healthy organs, including the bowel, lungs and thyroid. NCI, 2022.

A treatment’s balance of benefit and harm depends on the risk it addresses. Someone recovering from high-risk melanoma faces a different decision from someone without a cancer diagnosis. A favourable result in the first situation cannot establish an acceptable balance in the second.

Prevention still needs its own evidence

For a healthy reader, this trial supplies no reason to change cancer screening or seek an immune treatment. Its participants, intervention and measured outcomes do not answer those questions.

Even within melanoma, prevention evidence must be assessed separately. A Queensland randomised trial followed 1,621 adults assigned to daily or discretionary sunscreen use. Investigators subsequently identified 11 primary melanomas in the daily-use group and 22 in the discretionary-use group. The estimate for all melanomas was uncertain, with its confidence interval narrowly including no difference; the invasive-melanoma result favoured daily use but involved few cases. Green and colleagues, *Journal of Clinical Oncology*, 2011.

That study asks a prevention question directly. The vaccine trial does not replace it.

Current public-health guidance continues to emphasise reducing ultraviolet exposure through shade, protective clothing and sunscreen, and avoiding tanning beds. These remain practical measures, without a guarantee that an individual will avoid melanoma. US Centers for Disease Control and Prevention, 2026.

Personal experimentation has no evidential role here. Adding a supplement, changing a diet or tracking an immune marker cannot reproduce a tumour-specific vaccine trial or establish protection against recurrence. Those interventions were not tested by these studies.

If you have had high-risk melanoma, the findings justify a discussion with your oncology team about their relevance to your disease stage and previous treatment. If you have not, there is no new preventive intervention to adopt from this result. The evidence needed to change that decision would have to come from prevention research in people like you.

Sources